T. Lorenz

发表

Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study).

R. Califf, C. Grines, A. Lincoff, 2001, The American journal of cardiology.

Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial.

V. Hasselblad, J. Tcheng, G. Hafley, 2001, JAMA.

Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery.

L. Liao, L. Shaw, J. Alexander, 2005, The American journal of cardiology.

Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial.

V. Hasselblad, J. Tcheng, G. Hafley, 2001 .

ESPRIT in context: pharmacology matters!

J. Tcheng, J. O'shea, T. Lorenz, 2001, European heart journal.

Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention.

W. Cantor, J. Tcheng, M. Madan, 2000, American heart journal.

Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study.

J. Hochman, J. Tcheng, N. Kleiman, 2002, Journal of the American College of Cardiology.

Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy.

S. Murphy, J. Tcheng, D. Cohen, 2002, American heart journal.

Pharmacodynamics and Pharmacokinetics of Higher-Dose, Double-Bolus Eptifibatide in Percutaneous Coronary Intervention

J. Tcheng, N. Kleiman, L. Jennings, 2001, Circulation.

Nonimmunogenicity of eptifibatide, a cyclic heptapeptide inhibitor of platelet glycoprotein IIb-IIIa.

M. Kitt, T. Lorenz, F. Macdonald, 1999, Clinical therapeutics.

A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis

P. Lipsky, N. Olsen, E. Matteson, 1996 .

Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention.

R. Califf, P. Teirstein, A. Lincoff, 2003, Journal of interventional cardiology.

Design and Rationale of the PREVENT III Clinical Trial: Edifoligide for the Prevention of Infrainguinal Vein Graft Failure

G. Moneta, A. Clowes, B. Seely, 2005, Vascular and endovascular surgery.

Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy.

S. Murphy, J. Tcheng, D. Cohen, 2001, The American journal of cardiology.

Integrelin for emergency coronary artery stenting

P. Teirstein, E. Topol, J. Muhlestein, 1996 .

Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Results of two phase II studies. The CD5 Plus Rheumatoid Arthritis Investigators Group.

P. Lipsky, V. Strand, N. Olsen, 1993, Arthritis and rheumatism.

The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study.

S. Goldhaber, Adrian F. Hernandez, R. Harrington, 2014, American heart journal.

Differential Effects of Citrate Versus PPACK Anticoagulation on Measured Platelet Inhibition by Abciximab, Eptifibatide and Tirofiban

D. Kereiakes, D. Phillips, Gilbert Kukielka, 2001, Journal of Thrombosis and Thrombolysis.

Maximal benefit of integrelin platelet IIB/IIIa blockade 6–24 hours after therapy: Results of the IMPACT-II trial

R. Califf, E. Topol, A. Lincoff, 1996 .

Effects of an anti-CD5 immunoconjugate (CD5-plus) in recent onset type I diabetes mellitus: a preliminary investigation. The CD5 Diabetes Project Team.

J. Skyler, G. Eisenbarth, S. Schwartz, 1993, Journal of diabetes and its complications.

The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics.

Robert M Califf, R. Califf, M. Mack, 2005, American heart journal.

Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy.

R. Harrington, C. Dyke, S. Marso, 2000, The Annals of thoracic surgery.

The design and rationale for the APEX study (Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban)

S. Goldhaber, Adrian F. Hernandez, R. Harrington, 2013 .

Human parvovirus B19-associated disease in bone marrow transplantation

W. Wilmanns, G. Ledderose, C. Thomssen, 1999, Infection.

Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators.

R. Califf, E. Topol, M. Simoons, 2000, Circulation.

Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF).

V. Hasselblad, R. Califf, C. O'connor, 2009, American heart journal.

Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.

R. Califf, M. Mack, E. Peterson, 2005, JAMA.

Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein.

A. Eerenberg, N. Friedmann, N. Wedel, 1995, The Journal of infectious diseases.

Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery.

Scott A Berceli, G. Moneta, S. Berceli, 2006, Journal of vascular surgery.

Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results.

Eric M. Reyes, R. Califf, M. Mack, 2012, American heart journal.

Population Pharmacokinetics (PK) and Pharmacodynamics (PD) of Integrelin, a Platelet Aggregation Inhibitor

J. Tcheng, M. Kitt, T. Lorenz, 1996 .